Cargando…

Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice

Here, we investigate the potential of CD70 co-expression during viral vector boost vaccination to improve an antigen-specific T cell response. To determine the chance of activating antigen-specific T cells by CD70, we used the HBV core antigen as a model antigen in a heterologous protein-prime, Modi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephan, Ann-Sophie, Kosinska, Anna D., Mück-Häusl, Martin, Muschaweckh, Andreas, Jäger, Clemens, Röder, Natalie, Heikenwälder, Mathias, Dembek, Claudia, Protzer, Ulrike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966001/ https://www.ncbi.nlm.nih.gov/pubmed/36851121 http://dx.doi.org/10.3390/vaccines11020245

Ejemplares similares

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection
por: Kosinska, Anna D., et al.
Publicado: (2021)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Priming with a Recombinant Pantothenate Auxotroph of Mycobacterium bovis BCG and Boosting with MVA Elicits HIV-1 Gag Specific CD8(+) T Cells
por: Chapman, Rosamund, et al.
Publicado: (2012)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection
por: Kosinska, Anna D., et al.
Publicado: (2019)

TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia)
por: Jayakumar, Asha, et al.
Publicado: (2011)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
por: Perdiguero, Beatriz, et al.
Publicado: (2018)

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2023)

A single dose of SAAVI MVA-C reboosts rhesus macaques after more than 3 years post DNA-MVA prime-boost vaccination
por: Chege, GK, et al.
Publicado: (2012)

Installation of a 70 MVA Power Transformer
por: Balle, Christoph
Publicado: (2013)

Blocking sense‐strand activity improves potency, safety and specificity of anti‐hepatitis B virus short hairpin RNA
por: Michler, Thomas, et al.
Publicado: (2016)

Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key?
por: Willimsky, Gerald, et al.
Publicado: (2013)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

A DNA Prime and MVA Boost Strategy Provides a Robust Immunity against Infectious Bronchitis Virus in Chickens
por: Chandrasekar, Shaswath S., et al.
Publicado: (2023)

Antigen-dependent competition shapes the local repertoire of tissue-resident memory CD8(+) T cells
por: Muschaweckh, Andreas, et al.
Publicado: (2016)

Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems
por: Kugler, Franziska, et al.
Publicado: (2019)

Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity
por: Lauterbach, Henning, et al.
Publicado: (2013)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
por: Morelli, María Paula, et al.
Publicado: (2020)

Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
por: Ba, Lei, et al.
Publicado: (2007)

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8(+) T Cell Responses
por: Ring, Sandra S., et al.
Publicado: (2020)

Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza
por: Ballesteros-Tato, André, et al.
Publicado: (2010)

S100A9 Tetramers, Which are Ligands of CD85j, Increase the Ability of MVA(HIV)-Primed NK Cells to Control HIV Infection
por: Moreno-Nieves, Uriel Y., et al.
Publicado: (2015)

Airway delivery of both a BCG prime and adenoviral boost drives CD4 and CD8 T cells into the lung tissue parenchyma
por: Kaveh, Daryan A., et al.
Publicado: (2020)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
por: Joachim, Agricola, et al.
Publicado: (2015)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
por: Viegas, Edna O., et al.
Publicado: (2018)

Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines
por: Kittler, Julia M., et al.
Publicado: (2019)

Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack
por: Bonilla, Weldy V., et al.
Publicado: (2021)

Cd8(+) but Not Cd8(−) Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
por: den Haan, Joke M.M., et al.
Publicado: (2000)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice
por: Jongwe, Tsungai Ivai, et al.
Publicado: (2016)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

Self-adjuvanting nanovaccines boost lung-resident CD4(+) T cell immune responses in BCG-primed mice
por: Files, Megan A., et al.
Publicado: (2022)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
por: Stutz, H, et al.
Publicado: (2009)

Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice
por: Chapman, Ros, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_retsg885513v27m4lf4qmg5de3